SCHEMBL7124188

SCHEMBL7124188

Cc1ncn(-c2cccc(Nc3ncnc4c3CCc3ccc(F)cc3-4)c2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 3/20 0.35
EGFR P00533 4/20 0.35
ABL1 P00519 1/20 0.35
ABL2 P42684 1/20 0.35
MAPT P10636 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HTT P42858 2/20 0.34
LMNA P02545 1/20 0.34
RAF1 P04049 1/20 0.34
MAPK1 P28482 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ABCG2 Q9UNQ0 1/20 0.33
BRD4 O60885 1/20 0.33
CREBBP Q92793 1/20 0.33
PSEN1 P49768 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7119182 0.84 MKNK1 (0.35) MKNK1EGFRABL1ABL2MAPT
SCHEMBL7119959 0.84 PSEN1 (0.40) MKNK1EGFRABL1ABL2MAPT
SCHEMBL7119176 0.76 RIPK2 (0.39) MKNK1EGFRABL1ABL2MAPT
SCHEMBL7125546 0.73 BRD4 (0.45) MKNK1EGFRMAPTNPC1RAB9A
SCHEMBL7115935 0.72 DYRK1A (0.40) MKNK1EGFRMAPTHTTCYP2D6
SCHEMBL7122204 0.72 DYRK1A (0.40) MKNK1EGFRPSEN1PSEN2APH1B
SCHEMBL7128457 0.71 RAB9A (0.38) MKNK1EGFRMAPTNPC1RAB9A
SCHEMBL7118834 0.71 PSEN1 (0.40) MKNK1EGFRMAPTNPC1RAB9A
Hydrochloric Acid SCHEMBL7123978 0.71 DYRK1A (0.40) MKNK1EGFRHTTPSEN1PSEN2
Hydrochloric Acid SCHEMBL7117269 0.71 DYRK1A (0.40) MKNK1EGFRHTTPSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 MKNK1 2608/4885EGFR 319/4885ABL1 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.